Investors, Strategics & Innovators

Aiming to improve people's quality of life through investing in healthcare innovation.

Experienced medical device leader with a demonstrated history of success in multiple roles and geographies in two blue chip organisations. 

Experienced digital healthcare executive, with a demonstrated history of working in the hospital & health care industry. Skilled in Patient Flow, Strategic Planning, Commercial Management, Executive Leadership, and Change Management. Strong healthcare services professional with a Bachelor of Medicine, Bachelor of Surgery - MBBS focused in Medicine from University College London.

Bio coming soon.

I am an investor and business-outcomes focussed professional with over 12 years of experience in consumer insight and growth strategy consulting. Investing in and mentoring start-ups and scale-ups in the tech space.
I am deeply passionate about scaling-up and supporting companies seeking to transform the lives of patients/consumers/HCPs, driving impact, problem solving and building strategies, while fostering strong relationships with investors, clients and collaborators.

Strong vision and strategy skills. Good at understanding technology adoption trends. Significant experience in public and private high tech boards. Strong experience in investing at the seed/angel level in technology and life science. Seeking public company board position in a company that is re-thinking its strategy and would benefit from a strong visionary leader. Very experienced in rapidly growing auto safety systems from camera processors to Head-Up displays. More recently, gaining a lot of experience from investing in Life Science start-ups via KYTO. Active in the Band of Angels and the Keiretsu Forum.

Dr. Nehmé co-founded Digital Surgery in 2011 while training in plastic surgery in London and has continued to serve in his role after Digital Surgery was acquired by Medtronic in February 2020 to be integrated into the MITG Robotics division. Dr. Nehmé earned multiple awards for his research in innovation and application of surgical technology and simulation. He has presented at multiple international conferences and won the Founders Forum Singapore Rising Star award and the London Business School Deloitte Digital Health Award in 2015. Dr. Nehmé completed his masters in surgical technology at Imperial College London.

Experienced Research Director and Technical Fellow with a demonstrated history of working in the medical device industry. Skilled in Biomechanics, Biotechnology, Computational Modeling, Research and Development (R&D), and Life Sciences. Strong research professional graduated from University of Michigan Medical School and PhD in Computational Mechanics

Collaborate with Operational Units across the Medtronic Enterprise on advanced computer modeling and simulation applications; Management of academic collaborations and research projects; Exploring new technologies; Develop technology roadmaps & strategic plans.

Provide expertise and strategic direction in solid mechanics, biomechanics, tissue mechanics, and image-based modeling at Medtronic's Corporate Research Center. Expertise in injury biomechanics, FEA of composites and tissues. Perform project reviews, internal consulting, technical education, and manage external collaborations.

Steve has provided technical leadership in the design and development of technically advanced neuromodulation systems, including stimulators for the central and peripheral nervous system, implantable intrathecal pumps, and programming instrumentation.

He has experience in both individual and organizational innovation, including definition of R&D strategy, identification and assessment of disruptive technologies, and in managing a complex product pipeline.

Steve has led high performing, cross functional teams in software, systems engineering, and human factors.

Specialties: Strategic planning for research and product portfolios. Directed innovation for neuromodulation solutions including spinal cord stimulation, deep brain stimulation, peripheral nerve stimulation, and implantable infusion systems. System engineering for implantable devices and programmers. Human factors engineering for medical devices including user experience and interaction design. Software development (application and embedded). Design of handheld/portable instrumentation

Bio coming soon.

Raf has a decade of operational experience in the biotech sector and holds an M.Sc. in Biochemistry and Biotechnology and an MBA from Vlerick Business School. Subsequently, he spent more than 5 years at Korys, focusing on life science investments. He was involved with several young innovative companies and served as a strategic advisor for European and US-based investment funds.

Paul Tomasic is the Houlihan Lokey’s European Healthcare Investment Banking team.  He has more than two decades of healthcare investment banking experience, managing a wide variety of projects, from mergers and acquisitions to equity and debt capital raises for the broader healthcare sector, including work with medical technology, life sciences and healthcare services companies.

Prior to joining Houlihan Lokey, Mr. Tomasic was Head of RBC’s European Healthcare business and, before that, led Citi’s European healthcare business as a Managing Director. Earlier, Mr. Tomasic worked in UBS’ healthcare team and in L.E.K.’s life sciences consulting team . He began his career at Arthur Andersen in a tax structuring.

Paul graduated magna cum laude from New York University and earned a bachelor of laws from the London School of Economics.

Bio coming soon.

Bio coming soon.

Daniel O’Mahony is a Partner at Seroba and brings a wealth of experience in product development, strategic planning, licensing, corporate venturing, intellectual property management and commercialisation.

Daniel was involved in corporate venture at Elan Corporation from 1996-2003. He was an advisor and consultant to Kernel Capital venture capital fund from 2001 and a partner from 2008, focusing on investments in life sciences. He joined Seroba as partner in 2009.

Daniel graduated with a Ph.D. from the National University of Ireland, Cork in 1986 and holds a business degree in technology management from the Smurfit Business School, University College Dublin (2000). He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at University College Dublin. He has published in several scientific journals and is co-inventor on numerous patent families.

Dr O’Mahony currently sits on the boards of Atlantic Therapeutics and Perfuze. He previously sat on the boards of Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Medlumics, Stokes Bio (acquired by Life Technologies), Straatum (acquired by Lam Research Corporation), Novate Medical (acquired by BTG) and PQ Bypass (acquired by Endologix).

Alexander is a Partner at Endeavour Vision, investing in medical technology, digital health and diagnostics companies across multiple therapeutic areas.

Alexander brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of Kenbi, Relievant MedSystems, Lumeon, Rapid Micro Biosystems (NASDAQ:RPID) and VentureMed, and led the firm’s investments in Gynesonics, Nuvaira and V-Wave. He previously served on the boards of VertiFlex (acquired by Boston Scientific in 2019) and EndoStim. He is a member of the steering committee for PCR Innovators’ Day and serves as both a jury member and expert panelist for the Healthtech Summit.

Prior to joining the Endeavour Vision team, Alexander spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co.

Alexander holds an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University

Global executive with more than 15 years of experience in the healthcare industry, leading mid-to-large size multinationals in the areas of business development, strategy and M&A. Experienced at leveraging inorganic growth to build sustainable businesses while further developing the organizational capabilities and the innovation pipeline of the organization. Team player used to leading in international multi-decision level environments through a focus on addressing change management, collaboration, and efficient decision-making.

Bio coming soon.

Fernando is an Investment Director at Endeavour Vision focused on medical technology, digital health and diagnostics investments, with a particular focus on orthopaedics, robotics, dental, ophthalmology, ENT and GI. Since joining the firm, he has undertaken multiple sector reviews, led deal screening efforts and participated in and directed a number of due diligence projects. Fernando represented Endeavour Vision as a board observer for SOPHiA GENETICS (NASDAQ:SOPH) prior to the company’s IPO in July 2021. He is currently a board observer at Virtual Incision Corporation. He was on deal teams for investments in Virtual Incision Corporation, InBrace, Lumeon, SOPHiA GENETICS and CeQur.

Prior to joining Endeavour Vision Fernando was an Engagement Manager at McKinsey & Company. There, he led numerous business strategy and organisational projects including therapeutic-area strategy, merger management, process optimisation, operating model re-design, corporate due-diligence and market access and launch preparation. Fernando worked across multiple geographies, including Switzerland, France, Germany, Belgium, UK, US and Brazil and sectors such as diabetes, specialty pharmaceuticals, infectious disease, wound care, surgical instruments, orthopedics and dental. Before McKinsey, Fernando led the development of several orthopaedic trauma solutions at Stryker Orthopaedics R&D in Switzerland – focusing on upper trauma and extremities.

Fernando holds an MEng degree in Biomedical and Mechanical Engineering from Imperial College London and the Swiss Federal Institute of Technology (ETH) Zürich. His Masters’ thesis was in cardiovascular fluid mechanics of stented arteries.

Samuel is a physician entrepreneur.

He started his career as a management consultant at McKinsey & Company in New York before moving to Boston to attend Harvard Medical School. As a second-year medical student, Samuel co-founded Allurion Technologies and built a fully-integrated, global medical device company from the idea stage to commercialization in more than 30 countries.

Samuel is a graduate of Yale College (summa cum laude) and Harvard Medical School. He was a Fulbright Scholar to France at the Pasteur Institute.

Prior to joining Lauxera Capital Partners, Charles Cornevin was a Senior Associate at Eurazeo where he focused on healthcare buyouts. Charles joined Eurazeo in 2017 as an Analyst after several experiences in M&A and Private Equity (Rothschild and Hudson Advisors / Lone Star Funds in Munich, Dublin and London).

Charles started his career as a generalist investor within the Eurazeo Mid-Cap team and has participated in the monitoring of the following investments: Odealim (incl. exit), Redspher, Dessange, and the Rosa Group. He then launched the Eurazeo Healthcare-dedicated strategy from scratch and completed two investments in 2021: Novair Group and PSIH.

Charles graduated from Paris Dauphine University with a Masters in Corporate Finance and Financial Engineering.

Founder of Panakes, Diana has over 20 years of international experience in managing Venture Capital investment funds, through which she invested in over 60 start-ups across Europe. After several years of experience in the strategic consultancy sector at A.T. Kearney, Diana worked as Senior Advisor in the Investment Banking division of Lazard. In 2001 she co-founded 360 Capital Partners, a leading pan-European Venture Capital firm. She is a member of several national and international committees (EU and US) for the selection and promotion of innovative start-ups. She has also co-founded and chaired the International Venture Club, an association that brings together the main European venture capital firms. She is frequently involved as Scientific Advisor to Life Sciences conferences and acting in or chairing juries for the allocation of public funds at Italian, European and US level (i.e. Premio Marzotto, Life Star Awards, EIC H2020 and National Cancer Institute-SBIR initiative).

Bio coming soon.

Florian has more than 20 years experience in the life sciences covering research, product development, business development and sales. He has worked for various medical devices companies such as Epigenomics AG, Brahms AG, ThermoFisher and most recently as CEO of DST GmbH, Germany. He was a visiting professor of IE Business School, Madrid, where he lectured in the Master in Biotechnology program and the Master of business administration. He gained investment experience working at one of the leading life science VC funds Inventages, in London as well as in his corporate function role at ThermoFisher.

Florian holds a Ph.D. & Master in Biology from the Universität Freiburg and an International Executive MBA from the IE Business School. His scientific research has been published in 18 peer reviewed journals including Nature Genetics.

Kevin joined MVM in 2016. Prior to MVM, he worked across the life science and healthcare sector as a consultant at Bain & Company. Kevin completed his PhD in Oncology at the University of Cambridge, where he conducted translational research in the field of neural development.

Anne has been running our in-house MedTech accelerator, MD Start, since she came on board as a partner in 2015.

She embodies the MD Start team’s hands-on approach: Anne is the founding and current CEO of both Gradient Denervation Technologies and Moon Surgical. She is a Board member of both SafeHeal and AblaCare — two companies where she was also founding CEO.

“What I like about this job is that it is about building products and companies,” Osdoit says. “It is very diverse. It is in different therapeutic areas, in different spaces with different technologies.”

Prior to joining Sofinnova, Anne held several key positions at Mauna Kea Technologies, a Paris-based medical technology company with global presence, developing a disruptive “optical biopsy” technology. She was closely involved in multiple financing rounds, including the company’s initial public offering on the Paris Euronext, a highly successful operation and the largest public listing for the sector that year.

Anne is an active angel investor and an independent board member of FeetMe and Cardiologs Technologies, two Paris-based e-health startups. Cardiologs was purchased by Philips in 2021.

Anne is a trained biomedical engineer from Ecole Polytechnique of Paris, France and Johns Hopkins University in Baltimore, Maryland. She holds additional degrees in Biostatistics and epidemiology applied to clinical trials (Université Pierre et Marie Curie), as well as Corporate Finance (London School of Economics).

Bio coming soon.

Bio coming soon.

Séamus has spent 30 years building businesses around new technology as founder, executive, CEO and board member. He was developing distributed object-oriented securities trading systems in the 1990s, big data and AI systems before they were cool, and one of the first large-scale enterprise SAS systems. He spent several years in China growing venture funded businesses. In 2015 he left Silicon Valley and moved to Ann Arbor where he is a mentor for TechStars, helped develop the SAE Connected Vehicle Professional program, and is a frequent speaker at industry conferences. He is a board member/investor/adviser to a number of technology companies, including including We Predict, SpinTech, Pathware, Invision.AI, Rally, and The Next Education. Seamus holds degrees in Computer Science and Accounting from the University of Manchester. Outside work, Séamus can be found racing around the thousands of miles of off-road bike trails in Michigan.

Bio coming soon.

Bio coming soon.

Evan is an Investment principal at Philips Ventures based in Amsterdam, and currently serves as a Director of Carevive and Siilo. He’s also a member of the investment council for imec.xpand’s hardware-based nanotechnology fund. 

Prior to joining Philips Ventures, Evan was the Chief Business Officer of RareCyte, a venture-backed life science company based in Seattle, Washington. Evan holds an MBA from the University of Oxford — where he was an OUI-SBS Fellow and graduated with distinction — and a bachelor’s degree from Gonzaga University.

Lukas joined us in 2019 and is a partner on the MD Start team. He is a medical doctor and was trained in General Surgery at the Universities of Heidelberg and Freiburg.

As a former surgeon, the hands-on approach at MD Start appealed to him. "We're not up there in the balcony giving the thumbs up or thumbs down" as entrepreneurs make their pitches, he says. “We build the story; we bring in the necessary assets; we create the company, often from scratch."

Lukas was a postdoctoral scientist at the Novartis Center for Immunobiology at Harvard University, where he conducted preclinical research on protective genes. Subsequently, Lukas completed a Fellowship at the University of Minnesota as Organ Harvest Fellow, where he participated in NIH-sponsored clinical trials on islet transplantation.

In 2007, he joined the life science investment team at Wellington Partners, a pan-European venture capital firm where he advanced to investment director and invested in several European early stage life science companies.

Lukas holds a summa cum laude doctorate from Humboldt University (Charité) Berlin. He also obtained a Global One MBA degree from RSM Erasmus.

Bio coming soon

Sascha Berger, PhD, joined the TVM Capital Life Science team in Munich in 2016. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as corporate finance aspects of the fund.

Sascha has a strong financial background with almost ten years of professional transaction and strategy experience. He has a track-record of concluding 20 M&A transactions, five of those he led as responsible project manager in his previous role as Senior M&A Manager in a PE backed global corporation. He was a core team member in a successful EUR 2.5bn revenue cross-border merger and successfully coordinated global merger clearance procedures (USA, China, EU, Korea).

Prior to this recent role, Sascha successfully advised multiple renowned clients in corporate finance and strategy projects working as (senior) consultant for PricewaterhouseCoopers and the Boston Consulting Group. He was selected for the global leadership development program in his previous role and was named a global high-potential in PwC.

Sascha studied technology management in Munich, Singapore and Boston and  holds a Master from Munich University of Technology with majors in entrepreneurial finance and chemistry, magna cum laude. In his master thesis he analyzed the specific challenges of biotech VC financing rounds. Later he completed his PhD studies in banking and finance while already working for PwC. He is a regular speaker on corporate finance topics for German universities and business schools.

During his studies he already supported TVM Capital Life Science part-time; he supported the IPO of a German technology company at Deutsche Bank and advised Private Equity funds at Deloitte in summer internships. He lived in Singapore and New York, co-founded a student initiative on Entrepreneurship in Munich and in his spare time enjoys triathlon and world travelling.

Catello Somma, MBA, joined the TVM Capital Life Science team in January 2020. He is active in deal flow generation, investment due diligence, deal and exit transactions, investor communication as well as fundraising support.

Catello is biotech start-up founder with more than ten years of clinical development and corporate development experience. Prior to this role, Catello worked for a mid-cap biotech where he supported the development of immuno-oncology assets, both internal and in partnership with big pharma, and the preparatory work for a successful licensing in opportunity.

Catello holds an MSc in Molecular biology and an MBA with major in finance.

Jack joined MVM in 2019. Prior to MVM, he was a consultant at Bain & Company, where he served global pharmaceutical clients and medtech clients and specialized in due diligence for private equity firms looking at potential assets in the healthcare and life science sectors.

Prior to consulting, Jack practiced medicine in the UK. He completed his MBBS at King’s College London and holds a masters in Mathematics from the University of Oxford.

Rebecca began venture investing in 2006 while at Oxford Capital, where she took responsibility for the Oxford Gateway Funds’ investments into healthcare and life science companies, and went on to become Director, Healthcare Ventures at Imperial Innovations (now Touchstone Innovations).

Her earlier career was as a marketing consultant to pharmaceutical and life science technology companies. Rebecca has a PhD in Genetics from Nottingham University and an MBA from Oxford University.

She joined Longwall Ventures after a couple of years sabbatical break spent exploring South America in a VW camper van and focuses predominantly on medical technology opportunities.

Frank has more than 20 years of venture capital experience in the health-tech sector. With his know-how gained from bringing several of his early-stage investments to a successful exit, he will support you in the growth of your company.

Jamie is an Investment Associate, bringing five years of investment banking experience, including almost two years of Healthcare experience to the team.

Jamie joined from the Healthcare investment banking team at Jefferies in New York, where he worked to advise clients through a number of transactions across both the public and private markets. These included buy and sell side M&A, IPOs and equity/debt financings. His most recent position was as an Associate, focused on mid-market Healthcare Services, Medical Technology and Medical Device businesses.

Prior to Jefferies, Jamie worked as an Investment Banking Analyst for PwC in New Zealand, assisting a broad range of clients through various transactions across numerous sectors. He holds a Bachelor of Commerce in Accounting and Finance and a Bachelor of Arts in Spanish from the University of Canterbury, New Zealand, and is also a CFA Charterholder.

Matthew joined Epidarex as an Analyst. While at Epidarex Capital, Matthew has been actively involved in deal sourcing including expanding Epidarex Capital’s reach and relationships with key universities in emerging hubs in the US.  He also focused on conducting due diligence on prospective investments on both sides of the Atlantic and portfolio management. Matthew also supports the firm’s fundraising efforts and LP reporting. Matthew is a Board Observer for AdoRx Therapeutics and Epidarex Exeed.

Prior to joining Epidarex, Matthew was the Program Manager for the Georgetown University Center for Drug Discovery where he was responsible for managing the daily financial and research operations for the Center as well as developing the Center’s annual budget and grant proposals.

Matthew is currently an instructor at the NIH Foundation for Advanced Education in the Sciences (FAES), teaching Biomedical Business Development for Scientists.  In his role as an instructor he leverages his experience at Epidarex to provide real world insights to NIH researchers interested in learning about the commercialization of life science innovations.

Matthew holds an M.S. in Biotechnology and a B.S. in Biochemistry from Georgetown University.

As the Vice President, Strategic Solutions, Claudia is responsible for designing and enabling the strategic growth plan by advancing commercial capabilities including key account management, business insights, health economics & market access, pricing, contacting, sales force effectiveness, and solutions architecture to achieve business objectives across Europe, Middle East, and Africa.

Mr. Krantz will attend Emerging Medtech Summit to scout for new opportunities and network with other strategics, investors and innovators.

Bringing nearly 20 years of experience in mergers, acquisitions and investing in healthcare and technology, Noam is building a portfolio of best-in-class medical technologies investments to compliment the strategic goals of the Johnson & Johnson Medical Devices sector.    

Noam earned a Bachelor of Science in Biology from University of California Santa Barbara and a Masters in Business Administration from Columbia Business School. He began his career in investment banking, specializing in technology and healthcare companies. He has held various business development roles at Inamed Corporation, Mentor Corporation and Johnson & Johnson.

Noam is driven to help companies by bridging strategy and financial considerations to facilitate mergers and acquisitions, equity investment and collaborations. 

Bio coming soon.

Mike Mogul is President and Managing Director of HealthpointCapital. Prior to Healthpoint, Mike was last President, Chief Executive Officer and Director of DJO Global, a $1 billion firm in the Orthopedic sector owned by Blackstone, and market leading in non-operative segments including Bracing and Physical Therapy equipment. DJO was also the fastest growing firm in Total Joint implants and Consumer Sports Medicine under his leadership. Prior to joining DJO, Mike served as Group President, Orthopaedics for Stryker Corp. managing Stryker’s global orthopaedic businesses, which represented approximately $3 billion in revenue. Additionally, in his 22 years in the musculoskeletal space at Stryker, Mike served as Managing Director of all of Stryker’s divisional segments in Germany, Austria and Switzerland. Mike is Chairman of the Board of Crossroads Extremity Systems and a Board Member of ProSomnus Sleep Technologies. Mike received a Bachelor of Science degree from the University of Colorado and has attended the Advanced Management Program at the Harvard Business School.

Bio coming soon.

Bio coming soon.

Bio coming soon.

A senior principal investor and healthcare innovation, corporate finance, business development and commercial strategy executive with over 23 years of multinational experience in Venture Capital, large pharma, early to mid-market stage bio/med tech companies, and investment banking. Over his career Andrew has established himself as a proven relationship builder and deal maker across all facets of the healthcare innovation continuum, from product concept development to launching best in class treatment modalities. During this time, Andrew cultivated a successful track record for building blue chip investor syndicates, growing businesses, and originating, negotiating, and executing pharmaceutical licensing, alliances/partnerships, and acquisitions that generated significant shareholder value and tangible financial returns.

His success as a healthcare venture capitalist and senior healthcare operating executive results from a unique ability to combine a strong clinical foundation in the underlying epidemiology of several therapeutic areas and tenured experience in clinical and program management with a successful track record in business development, new product creation, and commercializing innovation. This established track record is in no small part the result of Andrew’s ability to bridge the divide that often exists between these disciplines to create and achieve shareholder value that yields significant Net Cash on Cash exit multiples.

CEO and Director of Lux Health Tech Acquisition Corp (NASDAQ: LUXA), a $345M Special Purpose Acquisition Corp focusing on generational companies innovating at the intersection of healthcare and technology.

Bio coming soon.

J. Christopher Mizer founded Vivaris in June of 1998. Vivaris (formerly Lake Erie Capital) invests in and acquires middle-market businesses in a broad range of industries that are leaders in their market niches. Mr. Mizer serves as the chairman of each of the portfolio companies and guides key strategic decisions and their execution. He also serves as the operating president on an interim basis when companies are going through periods of ownership succession and new management team members are being assembled. 

Mr. Mizer is a former Vice President and Officer of the investment banking division of Key Capital Markets, where he focused on merger, acquisition, and financing projects for Fortune 500 clients, private companies, and successful entrepreneurs. Prior to joining Key Corp., he was Consultant in the Capital Markets practice with Ernst & Young. 

He began his career as a Research Assistant with The Center for Economic Issues, a think-tank focused on economic development. He earned the B.S. (biology, applied math), B.A. (economics), M.S. degrees (biology - neurogenetics), and MBA (finance, accounting) degrees from Case Western Reserve University. 

Christopher has taught business strategy, finance and entrepreneurship at the graduate level at Case Western Reserve University, John Carroll University, and the University of California, San Diego and at the undergraduate at San Diego State University.

Bio coming soon.

Bio coming soon.

Andy McGibbon has worked in the management consulting and life science industries, accelerating innovation across a wide range of company sizes. In 2017, he formed a consulting practice to support large and small medtech companies with defining business processes for identifying impactful unmet needs in healthcare and lead the subsequent efforts to identify, filter, and develop the associated innovations.

Prior to forming his consulting practice, Andy worked with medtech firms across the fields of cardiology, GI, ophthalmology, and pulmonology and worked as a life science strategy consultant with Capgemini Consulting.

Andy is a graduate of the Stanford University Biodesign Fellowship.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Eliott is the Managing Partner of Nodes Advisors and the Head of Corporate Finance Group. In his role, he oversees the company’s advisory functions globally, and leads the Corporate Finance activities across Europe, Switzerland and China.

Eliott has been an advisor for dozens of clients on early-stage investments since he first joined the Venture Capital industry. Prior to founding Nodes Advisors, he was an Investment Manager at Polytech Ventures, where he oversaw early-stage investments of ~USD 50M across Switzerland.

Before transitioning to Venture Capital, Eliott worked as a Strategy Consultant advising large healthcare and pharma companies on growth strategies, and helping Private Equity firms conduct Due Diligence on companies in the Gulf region.

Steven Leuridan, PhD, CFA, has a passion for all projects where engineering and finance meet, especially when focused on medical applications. Steven has a background in engineering and is a CFA Charterholder. During his period as a PhD researcher, Steven co-founded Equilli, a sleep products business. Steven has published extensively on his research, with over 50 international journal, book chapter or conference publications and is the holder of two patents. In parallel, Steven was active within a Belgian family office for which he served in several start-up or later stage boards as a Director or Observer. Steven’s first-hand experience with the valorization journey of academic research proved a natural fit for the portfolio companies Qbic is targeting.

Steven holds a MSc in Engineering Sciences and a PhD in Biomechanical Engineering, both from the University of Leuven. Steven is a CFA Charterholder.

Bio coming soon.

Raised in the melting pot of the Bay Area before attending USC to major in biomedical engineering, Tracy took to heart Theodore von Kármán’s famous quote: “Scientists discover the world that exists; engineers create the world that never was.”  In pursuit of creating a better world, she headed to medical school at Stanford where she quickly experienced firsthand the challenges of getting innovative products into the hands of clinicians to ultimately improve patient care.  

Pivoting to industry, Tracy spent several years in healthcare M&A, then moved to Novartis Diagnostics, where she worked with Linda.  As Chief of Staff to the President, she led strategy and built out the innovation pipeline, then headed global operations. More recently Tracy has been focused in digital health, where she advised a range of organizations, from early-stage startups to the Novartis Digital Accelerator Lab and the Bill and Melinda Gates Foundation, before joining Avestria. She is also a member of the Women’s Health Executive Committee at Springboard Enterprises.

A classically trained violinist, Tracy believes that art & creativity is a critical underpinning for “STEAM” education.  She’s a fan of swimming, baking, and impromptu dance parties with her daughter.

Over 25 years experience in the investment management, financial research and in the biotechnology and medical technology industry. PhD in life sciences and MSc in biochemistry and a masters degree in business administration from ETH Zurich. Previously senior equity analyst at Bank Julius Baer and in senior management positions with Sulzer Medica, Schneider and Boston Scientific. Board member of Vascular Dynamics, Valcare Medical, Shape Memory Medical, Cardialen and MicroOptx.

Coming soon.

Over 2 years of M&A experience with Citigroup in Paris.

Prior experience with Eurazeo Capital, Natixis and Mazars.

MsC in Finance and Strategy from Science Po Paris and University of Vienna.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Richard has worked across the innovation-to-business spectrum from biotechnology research to product development, marketing and commerce including company formation and leadership in both large and small organizations. Trained at Imperial College, London, his Ph.D. in microbial biochemistry was sponsored by the UK health service, where Richard worked as a senior scientist before transitioning to industry. He progressed to business and company development while maintaining technical leadership. He was a key member of the executive team that transformed Whatman plc, the UK industrial filtration company, into a global healthcare business that became GE Healthcare. During the last ten years he has worked for investors in diligence and turn-around roles, mostly in the United States. Richard provides pro-bona support to exciting start-ups, judges the annual international Katerva Innovation Awards and candidates for the MedTech Innovator program, and supports Level Eight investments as a board member or advisor. Away from business he loves sailing and intends to cross an ocean or two.

Business development, commercialization and marketing executive with deep operating experience in medtech industry and proven track record of organizational growth management and strategic market development in US and Asia.

Strategic advisor for various technology startups in digital health, healthcare services, life sciences and medical devices. Proud investor in SpringTide Investments, Yard Ventures and Spike Ventures.

Bio coming soon.

Bio coming soon.

Mark is an Investment Director with over 18 years’ venture capital experience, with particular expertise in the life science sector. He has been involved in all aspects of creating venture backed businesses, including sourcing new opportunities, working with founders and management teams to build valuable propositions, through to public market listings and trade sales. He has been a non-executive director of several private and public companies. Mark  has worked across several early-stage venture funds, including the RisingStars Growth Funds, the North West Fund for Venture Capital, Finance Yorkshire Seedcorm Fund, and is actively looking for new life science deals for the Northern Powerhouse Fund. He has been heavily involved in the following investments; Concepta plc, Evgen and Abingdon Healthcare.

Mark is a member of the Mercia Responsible Investment Committee – a Group-wide team committed to delivering the ESG strategy across the business.

Will joined the Mercia in 2011, and has over 16 years’ experience in venture capital. He is Managing Director, Regional Venture Funds heading up the team that provides support for entrepreneurs to build high-growth innovative companies. These funds provide risk capital for new and early-stage startups, both tech and non-tech, together with scale-up capital for ambitious, established growth businesses located throughout the regions.

Will is also responsible for investments in Intechnica and Azzure IT.

Mr. Gilbert is an executive advisor to Thomas H. Lee Partners.  He brings forty years of experience in strategic and operations value creation for life sciences and healthcare companies as an investor, executive, board member and advisor.

In addition to his role at Thomas H. Lee Partners, Mr. Gilbert works at Flagship Pioneering where he supports the firm’s strategic development, value growth, nutritional health and health security activities.  Prior to Flagship, Mr. Gilbert served as a senior advisor to the investment firm General Atlantic and as a senior operating executive at Welsh, Carson, Anderson & Stowe.  Prior to those roles, Mr. Gilbert served as group president of the Global Cardiovascular Group and executive vice president of corporate strategy, business development, marketing and health economics and reimbursement at Boston Scientific. Prior to that, Mr. Gilbert worked at Bain & Company for over twenty-four years serving as chairman on the management committee, and the managing director of Bain’s Global Healthcare Practice with a focus on serving medical technology, biopharmaceuticals and life science tools clients. As a leading member of Global Strategy Practice at Bain, Mr. Gilbert was a published author and speaker, sharing insights on medical technology and pharmaceutical industry strategic trends and issues as well as “profit pool-based” and “strategic principled-based” strategy implementation.

Mr. Gilbert holds a B.S. in industrial engineering and operations research with high distinction from Cornell University School of Engineering and an M.B.A. with distinction from Harvard Business School.

Sascha joined RBVC in 2018 and is located in the Stuttgart office. Prior to Bosch, as Head of Venture Capital, he was responsible for managing the Seed-and VC-Funds with their broad investment focus as well as heading the Venture Capital Team at a local investment company. By leading numerous transactions, he backed his strong transaction and financial experiences. Before heading the team, Sascha gained experience as Investmentmanager in this sector. Prior to focusing on VC investments, he started his career as Consultant in Corporate banking. Sascha holds a bachelor degree in Business Administration of the Baden-Württemberg Cooperative State University and the CPEA certificate from the Technical University Munich.

Bio coming soon.

Bio coming soon.

Global strategic leadership experience within the health care and biomedical industries with a focus on delivering innovative products and systems that advances patient care.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Howard Leonhardt is an inventor and serial entrepreneur.  He has 21 U.S. patents for products for treating cardiovascular disease.  His TALENT stent graft developed in the early 1990′s holds a leading world market share for repairing aortic aneurysms without surgery.  His inventions have treated over 200,000 patients in 60 countries.

Bio coming soon.

Bio coming soon,

Bio coming soon.

Bio coming soon.

Nicolas Foin is a Founder & Managing Director at Dhenin Management.

Dhenin mission is to bring to market and grow disruptive solutions that are addressing large pain points in healthcare. 

Nic started his career with the Imperial College Cardiology research unit and National Heart Centre Singapore. 

He worked then in Market development, Strategy & BD in the Image Guided Therapy team at Philips Healthcare. 

He brings 15 years of experience across healthcare innovation and business development. He has served in executive role and advisory board for several healthtech start-ups and large players.  

Nic graduated with a MSc and PhD in Engineering in Medicine from Imperial College London. He is adjunct Associate Professor at the Duke-NUS Medical School Singapore, and serves in the executive board of CoreAalst, a clinical research incubation company. 

What he is most passionate about currently : Intelligent SaaS tech that are reducing costs and operational inefficiencies in our industry. 

Yann GOUËFFIC is the Head of Vascular Surgery Department at the Nantes CHU, the president of clinical trials department at Hospital of Saint Joseph.
He also is board member of the Meet congress as well as the head of Treasure of the French society of vascular and endovascular surgery.

He recently joined ECLEVAR as a scientific board member to help establish quality reimbursement routs (clinical and medico-economics data) is crucial to obtain the reimbursement and provide expertise in setting up clinical trials in France.

Pr. Luc Téot is the head of the Burns Unit and Wound Healing Unit of the Montpellier University Hospital in France. He is author of over 100 publications and wrote several books and book chapters.

He is an editorial board member of 8 journals and former president of the World Union of Wound Healing Societies and the European Tissue Repair Society.

He teaches as professor at the universities of Montpellier, Nantes, Limoges, Antilles and La Réunion. His passion for wound healing and scarring has encouraged him to become organiser of international conferences like Scar Club, Conférence de Plaies et Cicatrisation and the International Workshops on Wound Technology. Prof. Téot is qualified in General, Orthopaedic and Plastic surgery.

Camilla has a wealth of experience in both clinical and regulatory spaces. Since qualifying as a doctor, she has been working at the MHRA for over 8 years, with a period of time spent at SGS during this time as well. In her current role, she has been responsible for leading the consultation and development of the UK regulations for medical devices following Brexit, and is involved with policy makers, regularly interacting with ministers and decision makers.

A Medical Technology and Life Sciences products leader with over 20 years of progressive global, sales, marketing and operations experience and proven ability to consistently outperform expectations. Analyze markets, identify opportunities and create and implement strategies to achieve marketplace dominance. Develop relationships with key opinion leaders to influence potential customer perceptions. Entrepreneurial mindset with collaborative approach. Manage cross-functional teams and relationships with partners and affiliates worldwide

With a MSc in Clinical Trials from the University of Caen and a degree in Biology from the University of Paris-6 in Paris, Chems HACHANI is an expert in medical device clinical trials with more than 10 years of experience in European medical device clinical investigations. After holding positions in Ceiso’s clinical operations department, he joined Septodont, clinical affairs department and then Maetrics and was appointed Senior Medical Writer and then Chief Manager in 2015.
He has personally played a leading role in obtaining regulatory approvals for several significant European trials of advanced medical technologies.

Jan is the Founding Managing Partner of Valiance. He brings over 20 years of experience in growth investing. He leads the Investment Committee for the Valiance Funds and is responsible for all aspects of the Funds’ investment processes. Jan currently serves on the Board of several Valiance entities funds and portfolio companies including MDxHealth, JenaValve, MyCartis and 4Tech.

Prior to founding Valiance, Jan was CEO of La Fayette, where during his tenure the La Fayette Funds increased in AUM from $750 million to $5.5 billion. Before that, he was responsible for the Permal Group’s European-based investment management and research activities, and prior to that he worked at Lazard in Corporate Finance M&A.

Jan holds a BA in Business Economics from Gent University in Belgium, and a Masters in Banking & Finance from the University of Aix-Marseille, France.

Bio coming soon.

Chris joined Kreos in 2016 and is responsible for deal sourcing, execution, and monitoring. Prior to Kreos, Chris was a management consultant at the Parthenon group and has held corporate finance roles at Ernst & Young and Deutsche Bank. He holds a BCom in finance and economics from the University of Otago, is a CFA Charterholder and a Chartered Accountant with the Institute of Chartered Accountants Australia & New Zealand.

Kyle leads origination efforts for the firm’s Growth Business and Long-term Capital investment strategies. He is responsible for generating new opportunities by sourcing mission-driven businesses with ambitions to address social and environmental challenges at scale.

Kyle works closely with the teams to develop and explore attractive investment themes and business models. He leads on managing advisory relationships and seeks to build the Bridges brand across the business community.

Prior to Bridges, Kyle worked at Lloyds Development Capital for three years. He began his career in the Commercial Team at start-up Formula One outfit, Virgin Racing.

Kyle has a BA Honours degree from Nottingham University, is a qualified management accountant, speaks fluent Spanish and sits on the Board of Trustees for the Bridges Impact Foundation.

David Prim, PhD, is a Senior Associate at Broadview Ventures.

David broadly supports the Broadview investment team in its day-to-day operations, including identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement.

Prior to joining Broadview, David was a Senior Associate at Locust Walk, a global life sciences transaction firm, where he led engagements for biopharma and medtech clients guiding corporate development strategy and supporting sell-side, buy-side, and financing deal execution. Previously, David was a consultant a ClearView Healthcare Partners, a premier life science strategy consulting firm, where he supported completion of high-impact strategy projects for a broad range of industry clients across all aspects of the product lifecycle, including new product planning, R&D, commercial, medical affairs, market access, and lifecycle management.

David earned a PhD in Biomedical Engineering from the University of South Carolina, where his research focused on vascular grafting. His research projects covered a wide range of vascular mechanics, hemodynamics, and tissue engineering, with a specific focus on understanding and improving remodeling of coronary artery bypass grafts. David also holds a BS in Biomedical Engineering from the University of South Carolina with honors from the South Carolina Honors College.

David serves on the Board of Directors for Puzzle Medical Devices.

Virginia is an accomplished innovation executive with experience spanning Fortune 500 companies to start-ups. She is focused on accelerating disruptive, early stage innovation in healthcare. She works collaboratively, fostering partnerships to access external innovation, as well as to drive internal innovation by setting and aligning strategy, inspiring team and addressing internal barriers to innovation. She believes in the importance of customer- and patient-centric innovation, and to that end, looks for opportunities to be immersed with clinicians in hospital and other healthcare settings.

She has achieved outstanding results, across a spectrum of R&D leadership roles, resulting in launch of clinically impactful medical device products in the orthopaedic, cardiology, ENT and neurology spaces. She is an accomplished scientist, having authored numerous peer reviewed publications and been a frequent presenter at global healthcare conferences. She is a Fellow of the American Institute of Medical and Biological Engineering, the prestigious honorary society for Medtech Engineers.

Virginia also has significant management experience, having managed a variety of technical teams and projects with significant annual budgetary responsibility. She is sought after for her professional guidance and serves on several Advisory Boards.

Since 2016, I have led fundraising and closing on over $100M of seed/early stage Medtech deals resulting in the formation and development of seven new companies.

I joined the Coridea team in 2014 and currently function as the Chief Business Officer of Deerfield Catalyst, an incubator partnership between Coridea and Deerfield Management. My current responsibilities include innovation management, managing all financial aspects of the incubator and its portfolio companies, and business development.

I am a member of Wharton's 46th Executive MBA class. Prior to my career in healthcare, I attended the Berklee College of Music and continued my career producing music and managing artists through my production company that I began at age 16. During this period of time I also pioneered music technology programs in public schools throughout New York City and founded a travel consulting company to assist clients in acquiring and maximizing credit card points and miles. I am a board member of the Bronx Arts Ensemble, where I sit on the education committee.

Omid is currently a Managing Director at Anthro Ventures, investing across medical devices, diagnostics, digital health and healthcare services. Previously, he worked as an Investment Principal at MVM Life Science Partners LLP and Becton Dickinson as Director of Strategy and Business Development. Prior to that, Omid was a management consultant at Monitor Deloitte in the Life Sciences and Healthcare team. Omid holds a Masters in Bioengineering from the Johns Hopkins University and a Bachelors in Biomedical Engineering from the University of Virginia. He also received a Fulbright Award to conduct research on access to healthcare in the Middle East.

Dr. Nadine Hachach-Haram is a surgeon, lecturer and clinical entrepreneur. She drew on her passion for innovation, education and global surgery to co-found Proximie, an augmented reality platform that allows doctors to virtually transport themselves into any operating room, anywhere in the world, to visually and practically interact in an operation from start to finish. From marking up a patient to providing real-time virtual presence in assisting and instructing on an operation, Proximie aims to provide safe, accessible and cost-effective surgery to every patient around the world. Dubbed the "future of surgery" by CNN, Proximie has gone from strength to strength and won multiple awards as well as being the main focus of the Foreign Press Association Science Story of the Year. It aims to revolutionize the delivery and education of healthcare by reducing the cost of that delivery while providing improved quality to the end patient, ensuring that every patient gets the best care, the first time, every time.

After dabbling in politics and journalism at university, I started my career in management consulting, where I helped clients develop compelling strategies to adapt to evolving market needs. After business school, I gravitated to investment banking, where I advised technology, media, and telecoms companies on structuring, financing, and executing transformational transactions.

I found my calling in investing in early-stage companies as it offers the challenge and reward of partnering with talented founders to build new and better businesses faster. As an investor, I have focused on addressing material, everyday under-served needs with innovative data-driven products and services. I am motivated by tackling challenges that matter, and by leveraging technology to create positive, enduring change.

Not surprisingly this approach led me to healthcare, where every interaction involves important choices, costs, and outcomes, and the system needs to become more sustainable - affordable, accessible, equitable, empathetic, and effective. It also led me to initially partner with and then join General Catalyst. I experienced first hand the firm’s maker mentality at Livongo and the desire to serve those most in need at Cityblock. The General Catalyst ethos of radical collaboration is also well suited to healthcare, where entrepreneurs and traditional players need to work together to reinvent the future.

Two of the most important macro themes of the next decade will be the transformation of healthcare and the development of Europe into a technologically-driven economy. I could not be more excited by the opportunity to bring to bear the General Catalyst platform to support entrepreneurs in making a difference in these areas.

Whilst European, I consider myself a citizen of the world: I was born in Hong Kong, my parents are German and English, my wife is French and I have worked in the U.K., Europe, the U.S. and South East Asia. This is lucky as I work across multiple time zones and countries each day.

To clear my head, I spend time with family, read, travel, and play competitive sport. My family is actively involved in promoting ambitious environmental change and opening up higher education to less-privileged people from developing countries.

Coming soon.

Linus joined 415 Capital as an Associate in July 2019. Prior to joining 415 Capital, Linus worked for 4K Invest as an Associate in their Munich office and for RBC Capital Market’s London office as an Analyst in the Healthcare Investment Banking team. Linus holds a BSc. (Hons.) from King’s College London as well as an MPhil from the University of Cambridge.

Bio coming soon.

Coming Soon.

Christopher de Souza, PhD, MBA, is a Director at Broadview Ventures. He brings to this role over 30 years of experience in cardiovascular and metabolic related academic research, biopharmaceutical R&D, corporate strategy and business development.

Christopher started his pharmaceutical career at Novartis as a senior scientist in the Metabolic and Cardiovascular Diseases group and then as Director of Strategic Alliances with responsibilities for therapeutic area strategy, business development and alliance management. After Novartis, Christopher was Vice President of Business Development at SkyePharma US Inc., a drug delivery company, where he was responsible for out-licensing the company’s clinical assets and drug delivery technologies.

Christopher received a Masters in zoology from the University of Bombay, a PhD in physiology from Louisiana State University and an MBA from Rutgers University. He completed his post-doctoral training at The Upjohn Company and the Joslin Diabetes Center/Harvard Medical School.

Christopher currently serves on the boards of Acesion, Gila Therapeutics, Mellitus and Pulmokine and previously served on the boards of Allosteros, CellAegis, DecImmune, Herantis, NuPulse, Provasculon and Ventrinova.

Outside of Broadview Ventures, Christopher serves on the board of MassBio and has served on the grant review committees of the British Heart Foundation and NIH/NHLBI.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bryn spent 15 years working in the medical device industry, at Stryker, J&J and Smith+Nephew, in commercial and operations leadership roles. His MBA focused on business model innovation in digital health, which led to him deploying technologies across the value chain of surgery within blue chip and early-stage organisations. Before Proximie, Bryn was CSD at Digital Surgery.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Bio coming soon.

Dr. Robert Kieval, Executive Vice President of Strategic Partnerships

at Veranex, is an entrepreneurial and disciplined executive with over

20 years of CEO and C-level leadership experience in health care and

a track record of success in innovating, financing and commercializing

sophisticated medical technology. His career spans the top-tier in

MedTech, accelerators and start-ups, with positions including Medical

Director at Medtronic (NYSE: MDT) and Founder & CEO at CVRx

(NASD: CVRX).

Rob has been a longtime advocate for the medical device industry. He

has served on the Board of Directors of the Medical Device

Manufacturers Association, as a Director and Board Chairman at The

Medical Alley Association of Minnesota and has testified before

Congress on behalf of the industry. He was previously named an

Innovator of the Year by Twin Cities Finance & Commerce and as one

of Minnesota’s Top Inventors. Rob holds doctorate degrees in

Veterinary Medicine and in Physiology from The University of

Pennsylvania.

Bio coming soon.

Bio coming soon.

Luis Gutiérrez, chief commercial officer of Veranex, is a seasoned

business leader with a passion for helping companies bring new

medical technologies to market. He spent 19 years with the global

development services organization Covance, ultimately leading a 600-

person business unit that provides late-stage product development

services, including regulatory, market access, and health economic

consulting, as well as outcomes research and pragmatic clinical trials

for both drugs and medical devices.

He later served as chief commercial officer of Aptiv Solutions, a global

CRO with a focus on the medical device industry, and then led a

startup company providing molecular diagnostic services. He holds a

bachelor’s degree from Harvard University and an MBA from the

Stanford Graduate School of Business.

Pepe brings 30 years of business and management experience in the medical device industry and serves on the Board of Lungpacer, FEops, JenaValve, and Laminate.

Scott Carson established the first Internet distributor of new and pre-owned capital medical equipment to the healthcare industry, US Medical, Inc. He was part of the team that built the eBay Healthcare Marketplace structure and strategy and has won several industry awards, including Micro-Enterprise of the Year. Today, Mr. Carson is CEO of Powered by MRP and is a nationally recognized expert in driving sales via Internet Transactional Platforms.

An entrepreneurial strategic marketing professional with a distinct combination of package goods and healthcare marketing expertise from Tier 1 healthcare companies. This is complemented with experience in global product launch management and Silicon Valley start-ups.

Successfully led the development, launch and management of branded proprietary products in the categories of medical device, over the counter and prescription therapies.

Strengths: strategic marketing, global sales and marketing, new business development, new product development, portfolio management, direct to consumer marketing, Rx-OTC switch

Biography coming coon.

I love working with entrepreneurs and innovators that push the envelope of what's possible in life sciences. I leverage my clinical, technical and business experience to create, nurture, grow, and help partner startup companies. Whether it be through leadership, as an investor or board member, I always look to be a catalyst and accelerator of transformational innovation.

Bio coming soon.

Bio coming soon.

Bio coming soon.